Design, synthesis and biological evaluation of 5H-[1,2,4]triazino[5,6-b]indole derivatives bearing a pyridinocycloalkyl moiety as iron chelators

Wang, Cuifang
DOI: https://doi.org/10.1007/s11030-024-10840-w
2024-05-12
Molecular Diversity
Abstract:The avidity of cancer cells for iron highlights the potential for iron chelators to be used in cancer therapy. Herein, we designed and synthesized a novel series of 5 H -[1,2,4]triazino[5,6- b ]indole derivatives bearing a pyridinocycloalkyl moiety using a ring-fusion strategy based on the structure of an iron chelator, VLX600 . The antiproliferative activity evaluation against cancer cells and normal cells led to the identification of compound 3k , which displayed the strongest antiproliferative activity in vitro against A549, MCF-7, Hela and HepG-2 with IC 50 values of 0.59, 0.86, 1.31 and 0.92 μM, respectively, and had lower cytotoxicity against HEK293 than VLX600 . Further investigations revealed that unlike VLX600 , compound 3k selectively bound to ferrous ions, but not to ferric ions, and addition of Fe 2+ abolished the cytotoxicity of 3k . Flow cytometry assays demonstrated that 3k arrested the cell cycle at the G1 phase and induced significant apoptosis in A549 cells in dose and time-dependent manners, corresponding to JC-1 staining assay results. Western blot analysis of Bcl-2, Bax and cleaved caspase-3 proteins further provided evidences that induction of apoptosis by 3k in A549 cells might be at least via the mitochondria pathway. These above results highlight that 3k is a valuable lead compound that deserves further investigation as an iron chelator for the treatment of cancer.
chemistry, multidisciplinary, medicinal, applied
What problem does this paper attempt to address?